F-1/A: Evaxion Biotech A/S Files Amendment for Resale of Ordinary Shares Represented by ADSs

Evaxion Biotech A/S has filed an amendment to its registration statement for the resale of up to 19,453,796 ordinary shares represented by 1,945,379 American Depositary Shares (ADSs) by selling shareholders.

Summary

• Evaxion Biotech A/S has filed an amendment to its Form F-1 registration statement with the SEC.
• The filing pertains to the resale of up to 19,453,796 ordinary shares, represented by 1,945,379 American Depositary Shares (ADSs), by selling shareholders.
• These shares include 9,726,898 ordinary shares represented by 972,689 ADSs and an additional 9,726,898 ordinary shares represented by 972,689 ADSs issuable upon exercise of warrants at an exercise price of $0.707 per ordinary share (amended to 4.799 DKK as of June 12, 2024).
• The company will not receive any proceeds from the sale of these ADSs by the selling shareholders.
• However, Evaxion Biotech may receive up to an additional $6,876,917 in aggregate gross proceeds if the warrants are exercised.
• The company intends to use any proceeds from warrant exercises to advance its preclinical and clinical pipeline, and for continuing operating expenses and working capital.
• The ADSs are listed on The Nasdaq Capital Market under the symbol EVAX.
• On August 14, 2024, the closing sale price of the ADSs as reported on Nasdaq was $2.86 per ADS.
• Evaxion Biotech is identified as a foreign private issuer and an emerging growth company, which entails reduced public company reporting requirements.

Sentiment

Score: 6

Explanation: The document is primarily factual, detailing a securities registration for resale. While it highlights potential future funding, it also acknowledges risks and financial challenges, resulting in a neutral sentiment score.

Positives

• Potential for additional $6.8 million in gross proceeds if warrants are exercised.
• Funds from warrant exercises will support pipeline advancement and working capital.
• ADSs are listed on Nasdaq, providing liquidity for investors.
• The company has a clinical-stage oncology pipeline of novel personalized therapeutic vaccines and a pre-clinical prophylactic vaccine pipeline for bacterial and viral diseases with high unmet medical needs based on AI-Immunology identified vaccine targets.

Negatives

• The company will not receive any proceeds from the sale of ADSs by the selling shareholders.
• The company's stockholders equity of $(4,729,000) for the period ended December 31, 2023 was below the Stockholders Equity Requirement for continued listing.
• The company was granted an extension until November 4, 2024, to demonstrate compliance with the Rule to meet the continued listing requirements of Nasdaq, conditioned upon the Company evidencing compliance with the Rule.

Risks

• The company is dependent upon successfully concluding partnerships to advance our product candidates to monetize our assets.
• The company has incurred significant losses since its inception, and anticipates that it will continue to incur significant losses for the foreseeable future.
• The company will require substantial additional financing to achieve its goals, and a failure to obtain this capital on acceptable terms, or at all, could force the company to delay, limit, scale back or cease its product development activities or any other or all operations.
• The company's failure to meet Nasdaqs continued listing requirements could result in a delisting of the company's ADSs.
• The sale of a substantial amount of the company's ordinary shares represented by ADSs, including resale of the ordinary shares represented by ADSs issuable upon the exercise of the warrants held by the selling shareholders in the public market could adversely affect the prevailing market price of the company's ordinary shares.

Future Outlook

The company intends to use any proceeds from warrant exercises to advance its preclinical and clinical pipeline, and for continuing operating expenses and working capital.

Industry Context

Evaxion Biotech operates in the competitive biotechnology and pharmaceutical industries, focusing on AI-driven vaccine development.

Comparison to Industry Standards

• The document mentions a historical overall response rate of 40% with anti-PD-1 treatment alone in metastatic unresectable melanoma, against which Evaxion is comparing its EVX-01 results.
• Merck's KEYTRUDA (pembrolizumab) is a key comparator, as EVX-01 is being evaluated in combination with it.

Management Changes

Stakeholder Impact

• Shareholders may experience dilution from the resale of shares and potential warrant exercises.
• Employees may be affected by the company's financial performance and ability to fund operations.
• The company's ability to advance its pipeline could impact patients and the broader medical community.

Next Steps

• Selling shareholders may offer and sell the ordinary shares represented by ADSs from time to time.
• The company plans to use any proceeds from warrant exercises to advance its preclinical and clinical pipeline.
• The company plans to initiate a search for a candidate to assume Mr. Nissens responsibilities as the Chief Financial Officer.

Key Dates

Keywords

ADS, ordinary shares, warrants, resale, private placement, Evaxion Biotech, selling shareholders, registration statement, AI-Immunology, clinical pipeline